Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- “Favorable Transactions” for Nesp in Return for Support in Clinical Trial: Independent Panel
July 14, 2014
- Astellas, IBL to Study Manufacturing Method for Agent Utilizing Human Fibrinogen
July 14, 2014
- Takata Seiyaku Looks to Sales of 30 Billion Plus Yen by 2016
July 11, 2014
- Astellas Gearing Up to Expand Xtandi Indication Globally: Chief Medical Officer
July 11, 2014
- Astellas Selects Anticancer FLT3/AXL Inhibitor for Fast-Track Development
July 11, 2014
- Nippon Chemiphar Receives Approval for Actos Generic in Hong Kong: President
July 11, 2014
- Ono to Provide University of Tokyo with Access to Its Compound Library
July 11, 2014
- Bayer Yakuhin Adopts Unique Certificate Program to Train Cancer Sales Reps
July 10, 2014
- Novartis Lays Out New Global Guidelines for Investigator-Led Trials
July 10, 2014
- LSI Medience Develops Cardiotoxicity Assessment System Using Myocardial iPS Cells in NEDO-Driven Research Project
July 10, 2014
- Apeiron Begins PI Study of Neuroblastoma Immunotherapy Agent in Japan
July 10, 2014
- Vital-Net Makes Miyagi-Based Dispensing Pharmacy Chain Ohno its Subsidiary
July 10, 2014
- Bayer Yakuhin Sees Cancer Drugs as New Pillar
July 9, 2014
- MTPC to Up Japan Sales Force by 200-300 Partly via Job Transfers
July 9, 2014
- 31 Executives Received Annual Compensations for FY2013 of Over 100 Million Yen: Jiho Survey
July 9, 2014
- MTPC Aspires to Derive 30% of Sales from Offshore Biz
July 8, 2014
- Sanofi to Bounce Back with New Portfolios, Shift to “Mabs”: Pres.
July 7, 2014
- Sanofi’s Prostate Cancer Drug Cabazitaxel Gets Japan OK
July 7, 2014
- MTPC’s SGLT-2 Inhibitor Canaglu Wins Japan Approval
July 7, 2014
- European Commission Approves Expanded Indication for Halaven for Earlier Use in Breast Cancer Treatment: Eisai
July 7, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…